Hepatic artery administration of paclitaxel

Cancer Investigation

Volumn 17, Issue 2, 1999, Pages 118-120

  Walton, Gary D ^a,b   Schreeder, Marshall T ^a   Rizzo, Jinee ^c   Jobe, Donna Royston ^a   Kuhn, John ^c  

^a Comprehensive Cancer Institute ^*  (United States)

^b AUBURN UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL;

ADULT; ARTICLE; CASE REPORT; CRYOSURGERY; DRUG DELIVERY SYSTEM; HEPATIC ARTERY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAARTERIAL DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; MALE; PRIORITY JOURNAL; REMISSION;

EID: 0032971086     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1080/07357909909011726     Document Type: Article

References (19)

1. Breedis C, Young G: The blood supply of neoplasms in the liver. Am J Pathol 30:969-985, 1954.
2. Hohn DC, Stagg RJ, Friedman MA, et al: A randomized trial of continuous intravenous versus hepatic intra-arterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group Trial. J Clin 7:1646-1654, 1987.
3. Kemeny N, Daly J, Reichman B, et al: Intrahepatic or systemic infusion of flurodeoxyuridine in patients with liver metastases from colorectal carcinoma: a randomized trial. Ann Intern Med 107:459-465, 1987.
4. Rowinsky EK: Update on the antitumor activity of paclitaxel in clinical trials. Ann Pharmacother 28:S18-S22, 1994.
5. Rowinsky EK, Donehower RC: Paclitaxel (Taxol). N Engl J Med 332:1004-1014, 1995.
6. Huizing MT, Keung CF, Rosing H, et al: Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11: 2127-2135, 1993.
7. Sonnichsen DS, Liu Q, Schuetz EG, et al: Variability in human cytochrome P450 paclitaxel metabolism. JPET 275:566-575, 1995.
8. Cresteil T, Monsarrat B, Alvinerie P, et al: Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. J Clin Oncol 11:2127- 2135, 1994.
9. Sonnichsen DS, Hurwitz CA, Pratt CB, et al: Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 12:532-538, 1994.
10. Gianni L, Kearns CM, Giani A, et al: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13:180-190, 1995.
11. Murray N, Shah A, Osoba D, et al: Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J Clin Oncol 9:1632-1638, 1991.
12. Weirnick PH, Schwartz EL, Strauman JJ, et al: Phase I clinical and pharmacokinetic study of taxol. Cancer Res 47:2486-2493, 1987.
13. Brown T, Havlin K, Weiss G, et al: A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 9:1261-1267, 1991.
14. Shargel L, Yu AB: Applied Biopharmaceutics and Pharmacokinetics. Norwalk, CT, Appleton-Century-Crofts, 1985.
15. Brouer KL, Dukes GE, Powell JR: Influence of liver function on drug disposition. In: Applied Pharmacokinetics, 3rd ed., edited by WE Evans, JJ Schentag, WJ Jusko, Vancouver, WA, Applied Therapeutics, 1992, pp 6-1-6-59.
16. Hamel E, Lin CM, Johns DG: Tubulin-dependent biochemical assay for the antineoplastic agent taxol and application to measurement of the drug in serum. Cancer Treat Rep 66:1381-1386, 1982.
17. Longnecker SM, Donehower RC, Cates AE, et al: High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 71:53-59, 1987.
18. Wiernik PH, Schwartz El, Einzig A, et al: Phase I trial of taxol as given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 5:1232-1239, 1987.
19. Walle T, Wall UK, Kumer GN, et al: Taxol metabolism and dispo-sition in cancer patients. Drug Metab Disp 23:506-512, 1995.